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difference has been found when examining individual
cancers. Inter-domain correlations in each of the three
versions of the QLQ-C30 were strongest in Role Func-
tioning, Pain and Global Health Status. Cronbach’s reli-
ability measure shows improved reliability in newer ver-
sions of the questionnaire, for example, the pain scale
increases from 0.82 to 0.86 from version 1 to version 3.
CONCLUSION: We believe this is one of the first studies
to examine the scales of all three versions of the QLQ-
C30 with a large sample across a large number of coun-
tries and cancer sites. We found that in general all three
versions of the QLQ-C30 have similar psychometric
structures, that the measure proves to a be a useful tool
to use within a clinical trial setting and that missing data
is continually reducing over time, indicating increasing
compliance among staff/patients.
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OBJECTIVE: Quality of life (QOL) is becoming an ac-
cepted endpoint in cancer clinical trials. However, reports
suggest that fewer than 10% of clinical trials include QOL
assessment, it is believed that such reports may be biased
by time lag. This paper examines the extent of QOL stud-
ies that are conducted within one of the largest academic
cancer clinical trial organizations in Europe.
METHOD: Examination of all clinical trials conducted
by the EORTC (between 1990 to 2000) was undertaken
by reviewing databases, records and publications. Trials
were systematically selected if they involved any aspect of
QOL assessment. The protocols were then evaluated us-
ing criteria that evaluated the quality of trial designs and
methodology employed.
RESULTS: In total, 112 clinical trials involving over 10,000
patients were identified as having a QOL component. All
trials involved multinational patient recruitment, with the
highest recruitment from the Netherlands, France and Ger-
many, and lowest from Malta, Estonia and Slovakia. Ap-
proximately 25 disease groups have been actively recruiting
patients from disease groups of genito-urinary, breast and
lung cancers. A clear linear trend was noted, with increasing
numbers of clinical trials involving QOL components over
this period. Of these trials, 74 studies were Phase III, 15
Phase II and the remainder were feasibility studies. Pres-
ently, 45 trials are ongoing, 19 almost ready for data analy-
sis, 15 published and 10 being analyzed. In the last year, 30
studies involving QOL assessment have been submitted for
research, suggesting that QOL is a highly important end-
point in trials throughout Europe
CONCLUSION: While a decade ago QOL was not a ma-
jor component of EORTC clinical trials, it is now highly
integrated into trials, almost a standard secondary end-
point. In the European context, this suggests that clini-
cians and researchers are increasingly seeing the impor-
tance of patient-based outcome assessment methods.
PCN19
CHOICE OF OPTIMAL ANTI-EMETIC 
STRATEGIES IN CANCER THERAPY
Hartmann M
University of Jena, Jena, Germany
OBJECTIVE: Recommendations on the appropriate use
of corticosteroids (cort) and HT-3 antagonists (HT3A),
alone or in combination with benzodiazepines (benz) and
dopamine receptor antagonists (dopA) vary between
three and nine different anti-emetic strategies.
METHODS: We retrospectively compared the use of
anti-emetics in our clinical practice with the consensus
recommendations of Peruggia. We analyzed all patients
from a single department unit receiving chemotherapy on
an inpatient basis in February 2000.
RESULTS: One hundred thirty five days of chemother-
apy in 38 patients (20–78 years old, male/female 1,7/1)
suffering from various malignant diseases were included.
Five patients (13.1%) received anti-emetic therapy for
other reasons than preventing nausea and vomiting (e.g.
corticosteroids as comedication with paclitaxel). We
grouped the chemotherapy protocols as follows: very low
risk, (n  5); low risk, (n  44); moderate risk, (n  16);
high risk, (n  40); and severe risk, (n  30), according
to the Peruggia guidelines. We calculated the total theo-
retical consensus-guided costs for anti-emetic treatment
to be 2079.04 Deutsche Marks (DM) and the real costs
to be 2024.93 DM (hospital supplier prices).
CONCLUSION: We found a considerable drug-group-
related difference between consensus guidelines for anti-
emetic strategies and clinical practice. However, the total
expenditures did not vary significantly. We assume, that
the differences observed are due to patient-related factors
like history of nausea and emesis, tumor stage, tumor lo-
cation, sex, age, co-morbidity and alcohol consumption
rather than to chemotherapy. A computer-assisted anti-
emetic decision model (Emeto-Help) will be presented,
which includes both the drug-related emetogenic poten-
tial and the individual patient’s risk.
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OBJECTIVE: The aims of this study were: (1) to evaluate
the burden of influenza in terms of its impact on an indi-
vidual’s normal daily activities (including ability to work);
(2) to evaluate the beneficial effect of treatment with Osel-
tamivir on activity.
METHODS: The impact of influenza on the individual
was assessed by seven symptoms and a set of well-being
indicators. These indicators include the self-rated param-
eters for general health, sleep quality, overall level of ac-
tivity and paid work activity. This analysis is based on
pooled data derived from two double-blind, randomized
and stratified, placebo-controlled multi-centre studies
conducted in the winter season 1997/1998.
RESULTS: In the intent to treat infected population (ITTI),
median return to normal levels of daily activity was acceler-
ated by 2.7 days or by 27% when the patient received Osel-
tamivir instead of standard treatment (178.8 hours, 95%
CI 156.8 to 203.2, p  .0001 for Oseltamivir 75 mg com-
pared with 243.7 hours, 95% CI 206.5 to 276.2 for stan-
dard treatment). The greatest treatment effect was seen in
the population of patients eligible for work (ITTI, full,
part-time workers). In this population, median return to
normal levels of daily activity was accelerated by 4.5 days,
or an improvement of 41%. In this population, effects of
treatment also translated into a gain in number of hours
worked. Thus at day 7, the treatment effect on cumulative
hours worked was between 4.716 h (95% CI 2.32–7.11,
p  .001) and 3.755 h (95% CI 0.54–6.97, p  0.022) in
the 2 studies. This difference was detectable and statisti-
cally significant from day 4 of the illness onwards.
CONCLUSION: The impact of influenza on the daily ac-
tivities of those affected is large and should not be dis-
missed as trivial. Treatment with Oseltamivir has a sig-
nificant beneficial effect, particularly in the working
population.
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OBJECTIVE: Among persons with sexually transmitted
diseases (STD), the proportion that is also infected with
HIV is higher than in the general population. Since many
cases of HIV infection remain undetected during the as-
ymptomatic stage, HIV-infected patients are likely to per-
form the same sexual behavior as before and put partners
at risk of infection. Detection of asymptomatic HIV in-
fection will enable the person to protect partners by
changing sexual behavior, reducing the number of sec-
ondary transmissions. Therefore, HIV screening in clinics
for sexually transmitted diseases (STD-clinic) is a poten-
tial tool to control the epidemic. In our analysis we esti-
mate the cost-effectiveness of universal HIV screening of
patients attending a STD-clinic in Amsterdam.
METHODS: Cost-effectiveness analysis. A Bernoulli model
for the secondary transmission of HIV was linked with
epidemiological data on infection with HIV and other
STD in patients attending a STD-clinic in Amsterdam
from 1991 to 1997. This gave estimates of the number
of secondary HIV infections caused by visitors to the
STD-clinic. Combined with data on the health and mon-
etary benefits of averting HIV-infection and costs of
HIV-screening, we assessed the cost-effectiveness of HIV-
screening of visitors to the STD-clinic. Standard techniques
for cost-effectiveness analysis were used, and both costs
and life years gained were discounted at 4%.
RESULTS: Increased risk for HIV infection was found in
STD clinic attenders infected with another STD. (Odds
ratio: 2.07) The risk differed for different STDs, with the
highest odds ratios for syphilis and gonorrhea. Screening
of all attenders was estimated at a net cost of €82,552 per
secondary infection averted, with a cost-effectiveness ratio
of €1637 per life year gained (LYG). The cost-effective-
ness ratio ranges between €680 and €9335 per LYG, de-
pending on key parameters in the model.
CONCLUSION: Compared to other interventions in in-
fectious disease control in the Netherlands, this interven-
tion has an acceptable cost-effectiveness ratio.
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OBJECTIVE: To incorporate the cost of drug compliance
into existing estimates of the cost of treating HIV/AIDS
in Africa.
METHODS: Recent reports have estimated that the cost
of treating the AIDS epidemic in Africa could range be-
tween $1 billion and $10 billion dollars. These studies,
however, fail to account accurately for the impact of fail-
ing to comply with triple-combination highly active anti-
retroviral therapy for HIV/AIDS. Since non-compliance
has been demonstrated to have a significant effect on vi-
rological failure, and it is recognized that virological fail-
ure results in higher resource utilization, we incorporated
the link between compliance and resource utilization in
our analysis. As a base case, we used published estimates
of HIV/AIDS annual per-patient drug costs of $500 for
patients not experiencing virological failure (NVF) and
$1,000 for patients that do experience virological failure
(VF). The rate of virological failure has been reported to
range between 21.7% and 82.1% depending on compli-
ance rates ranging between 95% and 70%. Thus, we var-
ied the compliance rate to determine the associated impact
on virological failure and drug costs. We also conducted
sensitivity analyses on drug prices.
